In summary, combination treatment with ganetespib and lapatinib showed synergistic inhibition of the HER and downstream PI3K/Akt and Ras/MEK/ERK pathways, in addition to enhancing induction of early apoptotic cell death and G1 arrest in both lapatinib-sensitive and -resistant breast cancer cells. Here, MAP2K7 is linked to breast cancer.